BIO-RAD LABORATORIES INC.

ISIN: US0905722072 WKN: 090572207 Asset Class: Stock



Company Profile

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.						
Financial figures	2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity	
Current assets	3,048,330,000		3,157,976,000		1,989,088,000	
Common stock capital		3,000		3,000		3,000
Fixed assets	9,250,740,000		10,343,690,000		15,786,707,000	
Equity capital of a company		8,741,133,000		9,615,252,000		13,667,134,000
Cash and cash equivalents	403,966,000		434,228,000		470,797,000	
Accrued liabilities		900,000		0		400,000
Other assets	-		-		-	
Current liabilities		522,799,000		568,708,000		680,938,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		3,035,138,000		3,317,706,000		3,427,723,000
Different income		-		-		-
Other liabilities		194,213,000		185,812,000		171,291,000
Total accets	12 200 070 000	12 200 070 000	12 501 666 000	13 501 666 000	17 77F 70F 000	47 77F 70F 000

Other liabilities		194,213,000		185,812,000		171,291,000
Total assets	12,299,070,000	12,299,070,000	13,501,666,000	13,501,666,000	17,775,795,000	17,775,795,000
Balance notes						
				2023	2022	2021
Accounting standard				US-GAAP	US-GAAP	US-GAAP
Employees				8,030	8,200	7,900
Equity ratio				71.07%	71.22%	76.89%
Debt-equity ratio				40.70%	40.42%	30.06%
Others						
				2023	2022	2021
Tax Expense Rate				25.03%	22.89%	21.92%

BIO-RAD LABORATORIES INC.

ISIN: US0905722072 WKN: 090572207 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	2,671,262,000	2,802,249,000	2,922,545,000
Net income	-637,324,000	-3,627,535,000	4,245,902,000
EBIT	-830,251,209	-4,350,478,023	4,992,014,720
Operating income before taxes	-850,104,000	-4,704,273,000	5,438,149,000
Cash Flow	374,943,000	1,436,047,000	-425,779,000
Net interest income	51,461,000	19,886,000	17,349,000
Research and development expenses	226,927,000	256,789,000	258,357,000
Income taxes	-212,780,000	-1,076,738,000	1,192,247,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	306,347	314,706	340,680

Board of Directors

Members of Management Board				
Alice Schwartz	Member of Board of Directors			
Allison Schwartz	Member of Board of Directors			
Arnold Pinkston	Member of Board of Directors			
Gregory Hinckley	Member of Board of Directors			
Jeffrey Edwards	Member of Board of Directors			
Melinda Litherland	Member of Board of Directors			
Norman Schwartz	Chairman of Managing Board			
Ajit Ramalingam	Member of Executive Committee			
Andrew Last	Member of Executive Committee			
Annette Tumolo	Member of Executive Committee			
Dara Wright	Member of Executive Committee			
Ilan Daskal	Member of Executive Committee			
Mike Crowley	Member of Executive Committee			
Timothy Ernst	Member of Executive Committee			